All In MedTech

Device Trial Radar · NCT07858994

Effects of Fractional CO2 Vaginal Laser in Postmenopausal Women With Genitourinary Syndrome of Menopause

Effects of Fractional CO2 Laser on Angiogenesis and Collagenesis in Women With Genitourinary Syndrome of Menopause

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Nov 9, 2023

Primary completion

Jul 31, 2025

Study completion Jul 31, 2025

Sponsor

Lead sponsor
Karina Amar SvecAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 5, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Female only, from 45 years, up to 68 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated the effects of fractional carbon dioxide (CO2) vaginal laser treatment in postmenopausal women with genitourinary syndrome of menopause. Ten women underwent three fractional CO2 laser sessions at 30 to 40-day intervals. Clinical and vaginal assessments were performed before treatment and during follow-up. Vaginal tissue samples were collected at baseline, approximately one month after completion of treatment, and at long-term follow-up to evaluate histological changes, including collagen, vascularization, and estrogen receptor expression. Participants were followed through the long-term assessment performed approximately one year or more after treatment.

Conditions

  • Genitourinary Syndrome of Menopause (GSM)

Interventions

  • Fractional CO2 Vaginal LaserDevice

    Fractional microablative CO2 vaginal laser treatment was performed using the MTZ40 device with a 360-degree intravaginal probe. Treatment parameters were 28 W, pulse duration of 6.5 ms, and 45 DOTS. Participants received three treatment sessions at 30- to 40-day intervals. During each session, a single pass was performed along the vaginal walls, starting at the vaginal fornix and withdrawing the probe distally in 0.5-cm increments.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estrogen Receptor Alpha (ERα) Expression in Vaginal MucosaTime frame: Baseline, 30 days after the third laser session, and long-term follow-up (median 17 months after the third laser session)
  2. Microvascular Density Assessed by CD34 ImmunostainingTime frame: Baseline, 30 days after the third laser session, and long-term follow-up (median 17 months after the third laser session)
  3. Collagen Deposition in Vaginal MucosaTime frame: Baseline, 30 days after the third laser session, and long-term follow-up (median 17 months after the third laser session)

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Irmandade da Santa Casa de Misericórdia de São Paulo

    São Paulo, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.